{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PEG-Intron&page=2",
    "query": {
      "intervention": "PEG-Intron",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PEG-Intron&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T00:58:40.457Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00087607",
      "title": "Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alfa-2b (PEG-Intron)",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alfa-2a [Pegasys]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 385,
      "start_date": "2004-01",
      "completion_date": "2006-04",
      "has_results": true,
      "last_update_posted_date": "2016-07-01",
      "last_synced_at": "2026-09-04T00:58:40.457Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 36 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00087607"
    },
    {
      "nct_id": "NCT00402428",
      "title": "Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "albumin interferon alfa-2b",
          "type": "DRUG"
        },
        {
          "name": "peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Human Genome Sciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1331,
      "start_date": "2006-12",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2013-08-08",
      "last_synced_at": "2026-09-04T00:58:40.457Z",
      "location_count": 65,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 48 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402428"
    },
    {
      "nct_id": "NCT00548847",
      "title": "Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "GM-CSF",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Interferon-α-2b",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "1 Year and older"
      },
      "enrollment_count": 15,
      "start_date": "2007-01",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-10-26",
      "last_synced_at": "2026-09-04T00:58:40.457Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00548847"
    },
    {
      "nct_id": "NCT01443923",
      "title": "Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis",
        "HIV/AIDS"
      ],
      "interventions": [
        {
          "name": "Boceprevir",
          "type": "DRUG"
        },
        {
          "name": "Peg-Interferon-alfa 2B",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2011-09",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2015-07-13",
      "last_synced_at": "2026-09-04T00:58:40.457Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01443923"
    },
    {
      "nct_id": "NCT00305383",
      "title": "Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Viramidine",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alfa-2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 100,
      "start_date": "2005-11",
      "completion_date": "2007-05",
      "has_results": false,
      "last_update_posted_date": "2012-06-22",
      "last_synced_at": "2026-09-04T00:58:40.457Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • San Mateo, California • Bradenton, Florida + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00305383"
    },
    {
      "nct_id": "NCT00525031",
      "title": "Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Temozolomide (TMZ)",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon Alpha-2b (PGI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2006-08",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2020-09-23",
      "last_synced_at": "2026-09-04T00:58:40.457Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00525031"
    },
    {
      "nct_id": "NCT02168361",
      "title": "The SIM-SOF Trial for Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Pegylated Interferon alfa-2b",
          "type": "DRUG"
        },
        {
          "name": "Simeprevir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Center For Hepatitis C, Atlanta, GA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2013-12",
      "completion_date": "2015-04",
      "has_results": true,
      "last_update_posted_date": "2016-03-14",
      "last_synced_at": "2026-09-04T00:58:40.457Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02168361"
    },
    {
      "nct_id": "NCT00087568",
      "title": "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "peginterferon alfa-2a [Pegasys]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2003-01",
      "completion_date": "2006-03",
      "has_results": true,
      "last_update_posted_date": "2016-06-08",
      "last_synced_at": "2026-09-04T00:58:40.457Z",
      "location_count": 25,
      "location_summary": "Bakersfield, California • Pasadena, California • San Diego, California + 22 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Mateo",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00087568"
    },
    {
      "nct_id": "NCT02343224",
      "title": "Pegylated Interferon ALFA-2b in Children With Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Juvenile Pilocytic Astrocytomas",
        "Optic Pathway Gliomas"
      ],
      "interventions": [
        {
          "name": "Pegylated interferon alpha-2b",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "3 Years to 25 Years"
      },
      "enrollment_count": 9,
      "start_date": "2014-11",
      "completion_date": "2020-11-11",
      "has_results": true,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-09-04T00:58:40.457Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02343224"
    },
    {
      "nct_id": "NCT00036569",
      "title": "A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Intrinsic Pontine Glioma"
      ],
      "interventions": [
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "pegylated interferon alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 32,
      "start_date": "2002-05",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2012-02-13",
      "last_synced_at": "2026-09-04T00:58:40.457Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00036569"
    }
  ]
}